RBC Capital raised the firm’s price target on Nurix Therapeutics to $23 from $22 and keeps an Outperform rating on the shares. The company’s Q1 results recapped its recent partnership extensions that expand the its footprint in the inflammation & immunology space, the analyst tells investors in a research note. The oral STAT6 TPD is a solid add to the pipeline as a potentially high-value target with dupilumab-like prospects, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- 3 Best Stocks to Buy Now, 4/11/2024, According to Top Analysts
- Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
- Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
- Nurix Therapeutics reports Q1 EPS (76c), consensus (80c)
- Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
